10.5281/zenedo.15960797

NEXUS KNOWLEDGE PUBLICATION

https://nknpub.com/index.php/1

ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS

ISBN Number- 978-81-985724-7-9



Published By – Nexus Knowledge Publication

(Imprint of AKT Multitask Consultancy)

Bilaspur, Chhattisgarh, India, 495006

www.aktmultitask.com

Chapter- 7

DRUG INTERACTIONS AND THEIR IMPACT

SIJI C
Associate professor
National College of Pharmacy, Manassery, Mukkam, Kozhikode, Kerala
Pin - 673602
Email: csiji8050@gmail.com

DR. NALINI KANTA SAHOO
Dean
Faculty of Pharmaceutical Sciences, Rama University,
Kanpur Uttar Pradesh, India, Pin: 209217
Email: sahoo.nalini@gmail.com

AKSHADA ADHIKRAO SAPKAL
Assistant Professor
Gulabrao Patil College of Pharmacy Miraj
Pin - 416410
Email: akshadaborhade2018@gmail.com

ARCHANA SHIVALING KHILARE
Assistant Professor
Gulabrao Patil College of Pharmacy Miraj
Pin -416410
Email: akhilare16@gmail.com

DR. PREM SHANKAR GUPTA
Associate Professor
Department of Pharmaceutics, Teerthanker Mahaveer College of Pharmacy,
Teerthanker Mahaveer University,
Moradabad,
Pin: 244001
Email: premsgupta.rs.bme17@iitbhu.ac.in

10.5281/zenedo.15960797

Chapter 7….

DRUG INTERACTIONS AND THEIR IMPACT

SIJI C
Associate professor
National College of Pharmacy, Manassery,Mukkam,Kozhikode,Kerala
Pin - 673602
Email: csiji8050@gmail.com

DR. NALINI KANTA SAHOO
Dean
Faculty of Pharmaceutical Sciences, Rama University,
Kanpur Uttar Pradesh, India, Pin: 209217
Email: sahoo.nalini@gmail.com

AKSHADA ADHIKRAO SAPKAL
Assistant Professor
Gulabrao Patil Collage of Pharmacy Miraj
Pin - 416410
Email: akshadaborhade2018@gmail.com

ARCHANA SHIVALING KHILARE
Assistant Professor
Gulabrao Patil Collage of Pharmacy Miraj
Pin -416410
Email: akhilare16@gmail.com

DR. PREM SHANKAR GUPTA
Associate Professor
Department of Pharmaceutics, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh
Pin: 244001
Email: premsgupta.rs.bme17@iitbhu.ac.in

A crucial component of pharmacology, drug interactions have a big impact on the overall therapeutic results, safety, and effectiveness of medication therapy. These interactions take place when the presence of one medication changes the effects of another, potentially increasing the risk of side effects or improving therapeutic outcomes. Changes in medication absorption, distribution, metabolism, and excretion are only a few of the many processes that make up the intricate mechanisms behind drug interactions [1]. The many processes and kinds of drug interactions are examined in this chapter, with particular attention paid to interactions involving drug transporters, protein-binding, tissue-binding, and cytochrome P450-based interactions. In order to maximize pharmacological therapy, avoid negative consequences, and guarantee the safe use of many medications in clinical practice, healthcare providers must have a thorough understanding of these interactions.

7.1 INTRODUCTION TO DRUG INTERACTIONS

The pharmacokinetics and pharmacodynamics of one or both medications may be greatly impacted by drug interactions, which are complicated phenomena in which the presence of one substance changes the effects of another. Drug absorption, distribution, metabolism, excretion (ADME), or mechanisms of action may alter as a result of these interactions. To optimize treatment plans, avoid side effects, and enhance therapeutic outcomes—particularly for patients taking numerous medications—healthcare providers must have a thorough understanding of drug interactions [2].

7.1.1 Mechanisms of Drug Interactions

Drug interactions can happen in a number of ways that affect how medications are absorbed, distributed, metabolized, or excreted, changing their pharmacokinetic and pharmacodynamic characteristics. Because they can either enhance or decrease the effects of one or both of the medications involved, these interactions are important to understand because they can have a major impact on the clinical results of drug therapy.

10.5281/zenedo.15960797



Figure 1: Mechanism of Drug Interaction

Changes in drug absorption, changes in protein binding, and changes in drug metabolism, especially through enzymatic activities, are the main mechanisms that cause drug interactions.

- **Alterations in Drug Absorption**

The process by which a drug enters the bloodstream following administration is known as drug absorption, and it can be influenced by a number of factors. The way that one drug influences another's absorption is one of the main mechanisms of drug interactions. This can occur in a number of ways, including modifications to the gastrointestinal tract's pH, which can influence how soluble some medications are. For example, medications that raise the pH of the stomach (such as proton pump inhibitors) might decrease the solubility and, as a result, the absorption

of medications that need an acidic environment to dissolve, like iron supplements or some antifungal medications.

Drug absorption may also be impacted by modifications in intestinal motility. The amount of time available for a drug to be absorbed can be impacted by medications that change the rate at which the stomach empties or the way things pass through the intestines (such as laxatives or anticholinergic agents). While quicker motility may shorten the time the drug must be absorbed, thus lowering its bioavailability, slower stomach emptying time may cause delayed absorption.

- **Modifications in Protein Binding**

Protein binding changes are another frequent way that drugs interact with one another. Many medications go through the bloodstream attached to plasma proteins like albumin. The only pharmacologically active substance that can penetrate cell membranes and have an effect is the free (unbound) drug. There may be competition for binding sites when two medications attach to the same plasma protein. One drug can become free and potentially reach higher blood concentrations if it displaces another from its binding site, which raises the risk of toxicity.

For instance, if a medication like aspirin replaces a highly protein-bound medication like warfarin, the free concentration of warfarin may rise, potentially intensifying its anticoagulant effects and raising the risk of bleeding. On the other hand, several medications have the ability to attach to plasma proteins with such strength that they effectively decrease the number of binding sites available for other medications, hence diminishing the therapeutic effects of the latter [3].

- **Alterations in Drug Metabolism**

Changes in drug metabolism, especially through cytochrome P450 (CYP450) system enzymes, are frequently the most important mechanism of drug interactions. The presence of other medicines can affect the activity of a set of enzymes called cytochrome P450, which are in charge of the metabolism of a large number of different pharmaceuticals. Drug concentrations in the body can change as a result of drugs' ability to either stimulate or inhibit the action of these enzymes.

The process by which one drug raises the activity of a metabolic enzyme, causing subsequent medicines that are substrates of that enzyme to be metabolized more quickly, is known as drug induction. The efficacy of the impacted medication may be reduced as a result of subtherapeutic doses. The anticonvulsant medication carbamazepine, for example, is known to trigger

CYP3A4, which might speed up the metabolism of other medications, such as oral contraceptives, decreasing their effectiveness and perhaps increasing the risk of unwanted births.

Drug inhibition, on the other hand, happens when a drug reduces the activity of a metabolic enzyme, which results in a slower metabolism and higher quantities of other medicines that the enzyme metabolizes. For instance, CYP2C9, which is involved in the metabolism of warfarin, is inhibited by the antibiotic fluconazole. The risk of bleeding may increase as a result of this inhibition, which may raise blood levels of warfarin.

7.1.2 Types of Drug Interactions

Based on their characteristics and the results they yield; drug interactions can be divided into a number of categories. Pharmacokinetic and pharmacodynamic interactions are the two main categories of medication interactions [4]. While pharmacodynamic interactions impact the drug's activity at the receptor site or the target tissue, pharmacokinetic interactions entail modifications to the drug's absorption, distribution, metabolism, or excretion.

- **Pharmacokinetic Interactions**: When one medication changes how another is absorbed, distributed, metabolized, or excreted, these interactions take place. For instance, one medication may prevent another from being metabolized, which would raise the amount of the second medication in the blood.
- **Pharmacodynamic Interactions**: When two medications have antagonistic, synergistic, or additive effects at the receptor site, these interactions take place. Drugs with opposite effects on the central nervous system may cancel each other out, while two medications with similar effects on blood pressure may have an additive hypotensive effect.

7.1.3 Clinical Significance of Drug Interactions

The type of interaction, the therapeutic index of the drugs involved, and the patient's general health status are some of the variables that affect the clinical importance of drug interactions. While some drug interactions can result in serious side effects or therapeutic failure, others are often innocuous and have little effect on the patient's treatment plan. For instance, interactions that cause drug metabolism to be inhibited may result in toxicity because of the drug's accumulation, whereas interactions that cause drug metabolism to accelerate may lead to therapeutic failure because of the drug's decreased concentration.

In polypharmacy, which is prevalent in patients with several chronic diseases or in older persons, it is particularly crucial to identify and manage drug interactions. In certain situations, drug interactions may reduce the effectiveness of the medication, raise the possibility of adverse effects, and make it more difficult to manage the patient's health overall.

7.1.4 Prevention and Management of Drug Interactions

A proactive strategy from healthcare practitioners is necessary to prevent and manage medication interactions, which are a crucial aspect of pharmacotherapy. The medications being recommended, their dosages, and when to administer them must all be carefully considered. This guarantees that a patient's prescription medication combination won't result in unfavourable interactions that could jeopardize the safety or effectiveness of treatment.

Knowing the pharmacokinetic characteristics of the medications in question is one of the first steps in avoiding drug interactions[5]. Drug interactions in the body are mostly determined by pharmacokinetics, which encompasses the absorption, distribution, metabolism, and excretion (ADME) of medications. Drugs with similar metabolic routes, for example, especially those processed by the cytochrome P450 enzyme system, may compete for the same enzymes, resulting in subtherapeutic drug levels or drug accumulation. To reduce these dangers, healthcare professionals need to be aware of these characteristics.

When prescribing several drugs, especially to older patients or those with complex, chronic diseases, doctors need to be aware of pharmacokinetics and exercise caution. Drug-drug interactions are more likely to occur in these patients since they frequently take many drugs. For instance, over-the-counter supplements and prescription drugs used to treat chronic illnesses like diabetes, cardiovascular disease, or hypertension may interact. To find any drug interactions, medical professionals should carefully go over a patient's prescription list, including any herbal supplements.

One useful approach for avoiding interactions is the use of medication interaction databases and decision support systems. These databases are a trustworthy resource for physicians when writing prescriptions because they are updated frequently to take into account fresh research results and clinical recommendations. When an interaction is likely to happen, they can indicate known interactions, provide safer substitutes, or suggest changing the dosage. Healthcare professionals can enhance patient safety and lessen the possibility of negative interactions by integrating these tools into the prescription process.

10.5281/zenedo.15960797

Patient education is another essential component in managing and preventing medication interactions. Patients need to be informed about the possible dangers of taking specific medications together as well as the warning signals of potential interactions, like odd side effects or changes in the effectiveness of the medication. Reducing the likelihood of interactions can also be achieved by providing clear instructions on when to take medications, such as whether they should be taken with food or empty. In order for their care team to account for any potential interactions, patients should also be encouraged to tell their healthcare providers about all of the prescriptions they are taking, including vitamins, herbal supplements, and over-the-counter medications.

Last but not least, identifying and treating medication interactions requires routine monitoring of individuals undergoing polypharmacy. Physicians should keep an eye on blood drug levels, evaluate any new adverse effects, and modify dosages in response to patient response. By regularly monitoring patients' progress, medical professionals can see possible problems early on and take appropriate action before they become significant complications.

7.2 PROTEIN-BINDING INTERACTIONS

The term "protein-binding interactions" describes how medications attach to plasma proteins in the bloodstream, such albumin. The pharmacokinetics of medications and their total therapeutic effect may be greatly impacted by these interactions [6].



Figure 2: Protein Binding

The pharmacodynamic effects of a medicine depend on its free (active) concentration in the blood and tissues, which is determined by its capacity to bind to plasma proteins. Since the unbound substance can pass through cellular membranes to reach its target site, only the free form of a medication is pharmacologically active. Changes in protein-binding interactions can therefore affect the toxicity as well as the effectiveness of the medicine.

7.2.1 Impact on Drug Pharmacokinetics

One important pharmacokinetic characteristic of medications is their binding to plasma proteins, which affects the drug's absorption, distribution, metabolism, and excretion throughout the body. Many medications are transported by plasma proteins, mainly albumin, in the bloodstream, which affects the drug's activity and bioavailability. medications differ greatly in how much they attach to plasma proteins, and this binding process is reversible, which means that under specific circumstances[7], medications can be released from their bound state. Predicting how pharmaceuticals will operate in the body and how they could interact with other medications requires an understanding of these interactions.

- **Protein-Binding and Drug Activity**

Only a tiny portion of a highly protein-bound medication is in its free (unbound) form, which is the pharmacologically active form that can pass through cell membranes and reach its target locations. Drugs like phenytoin and warfarin, for instance, are known to be highly protein-bound (up to 99%), which means that the small amount of the medicine that is unbound and active in the bloodstream is crucial to their therapeutic benefits. On the other hand, a greater percentage of medications that are poorly protein-bound—like several antibiotics and antiepileptics—are available in their active form. Faster therapeutic effects may arise from this, but there is also a greater chance of adverse consequences because the drug might interact with target locations at higher concentrations.

The primary factor influencing drug activity is frequently the concentration of the unbound drug. Consequently, knowing the degree of protein binding can aid in forecasting the drug's efficacy and its side effects. For example, when a highly protein-bound medication is taken with another medication that also competes for binding sites, the first drug's total unbound concentration may rise noticeably. Its pharmacological activity may be improved, but the risk of toxicity may also increase, especially if the medicine has a limited therapeutic index. Digoxin and warfarin are examples of narrow therapeutic index medications that need close monitoring since even small variations in their free plasma concentration can have major clinical repercussions.

- **Displacement Interactions and Their Consequences**

The possibility of drug displacement is among the most significant clinical outcomes of protein-binding interactions. One medication may push the other out of its binding site when two medications that have a high affinity for plasma protein binding sites are taken

simultaneously. This displacement enhances the displaced drug's pharmacological impact by raising its free concentration. However, particularly for medications with a limited therapeutic index, this rise in free drug levels may also raise the risk of toxicity or unpleasant reactions. For instance, taking aspirin with the anticoagulant warfarin may cause warfarin to be displaced from its binding sites on albumin, increasing the amount of free warfarin and increasing the risk of bleeding problems.

Both medications' pharmacodynamics may change as a result of this displacement, and the pace of drug metabolism and excretion may also be impacted by the rise in free drug concentrations. Drug accumulation can occur when a drug's free concentration increases to the point that the body is unable to effectively remove it. For medications that are broken down by particular liver enzymes or removed by renal excretion, this is especially problematic. In order to avoid toxicity or therapeutic failure, clinicians need to be aware of certain drug interactions and modify dosages appropriately.

- **Effects on Drug Distribution, Metabolism, and Elimination**

Drug distribution, metabolism, and excretion can all be significantly impacted by protein-binding interactions. Since highly protein-bound drugs cannot easily cross cell membranes and tissues until they are released from their binding sites, they often have a slower distribution phase. As a result, certain medications may take longer to start working. On the other hand, medications with less protein binding are more likely to reach tissues and organs quickly, which may result in a quicker start to their effects. However, because the drug is removed from the body more quickly, this speedy dispersion may also result in a shorter half-life.

The length of a drug's therapeutic impact and its excretion from the body can be affected by how quickly it is released from its protein-binding sites. Highly protein-bound medications frequently have longer half-lives because the bound substance is released into the bloodstream gradually, resulting in a longer-lasting effect. Conversely, medications with less protein binding might be eliminated from the body more quickly, necessitating higher dosages to sustain adequate plasma levels. When choosing the best dosage and dosing schedule for a medication, these pharmacokinetic characteristics are essential.

Furthermore, the drug's metabolism may be impacted by protein-binding interactions, especially if the unbound drug is accessible for the liver's metabolic functions. A medication may enter the liver in greater doses if it is dislodged from its binding sites, which could cause metabolic pathways to become saturated. Longer-lasting effects and a slower metabolism may arise from this. On the other hand, the body may find it difficult to sustain therapeutic plasma

concentrations over time if a medication is removed more quickly, as is the case with medicines that have low protein binding. In such cases, dose intervals may need to be adjusted.

7.2.2 Clinical Significance of Protein-Binding Interactions

Since protein-binding interactions directly affect the pharmacokinetics and overall therapeutic results of pharmacological therapies, an understanding of them is essential in clinical practice. The amount of free (active) medication in circulation is largely determined by the ability of plasma proteins, such albumin, to bind proteins. Any change in protein binding can have significant effects on the safety and effectiveness of a medicine because only the unbound fraction of a drug is pharmacologically active.

- **Impact of Altered Protein Levels in Disease States**

The pharmacokinetics of medications can be dramatically changed by some medical disorders, especially those that impact protein levels. For instance, decreased production of plasma proteins like albumin, the main protein that binds many medications, is frequently the result of liver illness. Because there is less albumin available to bind to the medicine when albumin levels fall (hypoalbuminemia), there is freer drug in circulation. The risk of toxicity may rise as a result of an enhanced pharmacological impact. For example, highly protein-bound medications such as digoxin, warfarin, and phenytoin may be dangerous if used by patients who have liver illness or circumstances like malnutrition that cause a decrease in albumin synthesis.

Even minor adjustments to the drug's concentration can have a big therapeutic impact on these patients. For instance, elevated free drug levels might cause toxic consequences, including neurological symptoms like ataxia, nystagmus, and even coma, in the case of phenytoin, a medication with a limited therapeutic index. Therefore, in order to properly adjust medicine dosages and avoid side effects, it is crucial to monitor free drug levels in patients with altered protein binding. When prescribing such medications, clinicians must exercise caution, taking into account substitute treatments or modifying dosages as needed to account for variations in protein binding.

- **Drug Displacement Interactions**

The possibility of drug displacement interactions, in which one medication removes another from its protein-binding sites on plasma proteins, is another therapeutic worry. This is especially crucial for medications that have a high affinity for binding proteins since even little variations in how they bind to proteins can have a big impact on the concentration of free

medicine. For example, highly protein-bound medications such as sulfonamides have the ability to displace other medications from albumin, increasing the amount of free drug in the blood.

The interaction between warfarin and some antibiotics, including sulfamethoxazole-trimethoprim, is one prominent example. Due to its strong binding to plasma proteins, warfarin can be dislocated from its binding sites by sulfonamide antibiotics, increasing the amount of warfarin that is free. Patients who have a history of coagulation abnormalities or who are on warfarin for anticoagulation medication may be more at risk for bleeding as a result of this. In order to prevent excessive anticoagulation, individuals taking both medications at the same time need to be closely monitored, and warfarin dosages may need to be changed.

- **Drug-Drug Interactions and Therapeutic Implications**

When patients take many medications at the same time, a condition known as polypharmacy, the possibility of drug-drug interactions resulting from protein-binding displacement is especially worrying. Minimizing negative interactions in these circumstances requires knowing which medications are most likely to compete for protein-binding sites. The medications a patient is taking and the possibility of protein-binding displacement interactions are important considerations for clinicians. By keeping an eye on plasma medication levels and modifying dosages as necessary, side effects can be avoided and treatment objectives can be met [8].

The pharmacokinetic profile of one or both medicines may occasionally alter as a result of drug interactions. To maintain therapeutic efficacy, for instance, a drug's increased free fraction may speed up its metabolism, necessitating dose modifications or more regular monitoring. Furthermore, a drug may have an elevated pharmacological action or toxicity if it is displaced and its free concentration rises noticeably. This could be harmful, particularly in individuals who are elderly or have impaired organ function.

7.2.3 Strategies to Manage Protein-Binding Interactions

Careful drug selection and monitoring are essential for managing protein-binding interactions, particularly when several drugs are being used. Healthcare professionals must understand the possibility of displacement interactions and be cautious of medications with high protein-binding affinities. Patients receiving medications with narrow therapeutic indices or those whose illness conditions cause altered protein binding require regular monitoring of drug levels and patient response.

The likelihood of displacement interactions may occasionally be decreased by choosing medications with low protein-binding affinities. Additionally, when administering medications that modify liver function or nutritional status, or that influence protein levels, doctors should exercise caution. The possibility of negative interactions can be decreased by making changes to the prescription schedule, such as lowering the dosage of the displaced medicine or selecting substitutes with a lower binding affinity.

7.3 TISSUE-BINDING INTERACTIONS

Drugs that have an affinity for particular bodily tissues or organs may bind and aggregate there, influencing the drug's pharmacokinetics, effectiveness, and potential toxicity. This phenomenon is known as tissue-binding interactions [9]. Drugs and components within different tissues, including fat, liver, lungs, kidneys, and bone, interact during tissue binding, as opposed to plasma proteins, which are mostly in charge of distributing medications in the bloodstream. The distribution, length of action, and magnitude of the drug's therapeutic benefits are all significantly influenced by this interaction.

7.3.1 Mechanisms of Tissue Binding

comprehension a drug's pharmacokinetic and pharmacodynamic behavior requires a comprehension of the methods by which it binds to tissues. The distribution of a drug throughout the body, its duration of action, and the location of its effects can all be greatly impacted by tissue binding. In general, there are two main ways that tissue binding might take place: passive diffusion and active transport.

- **Passive Diffusion**

The most frequent way for medications to enter tissues is through passive diffusion. The drug travels from a location of higher concentration (often the blood plasma) to one of lower concentration (the tissue), which is driven by a concentration gradient. Drugs that are lipid-soluble (lipophilic) are more easily absorbed by lipid-rich cell membranes. These medications have the ability to attach to different intracellular substances including proteins, lipids, or nucleic acids once they are inside the tissue. How long the medication stays in the tissue and how soon it can return to the systemic circulation can both be impacted by the strength and reversibility of this binding.

For instance, diazepam and other lipophilic medications have a propensity to build up in adipose (fat) tissue. In addition to extending the drug's half-life, this produces a depot effect, in which the medication is gradually released over time. Long-term therapeutic levels may be

10.5281/zenedo.15960797

maintained by this method, although toxicity could result if buildup is severe or if the patient has a high body fat percentage.

➢ **Active Transport**

Active transport, on the other hand, utilizes certain transporter proteins that are implanted in cellular membranes and necessitates energy. These transporters have the ability to transfer medications into or out of tissues in opposition to concentration gradients. For medications that are not sufficiently lipid-soluble to diffuse passively, this process is especially crucial. Many transport proteins found in tissues such as the liver, kidney, and brain control medication entrance and departure and are frequently essential for organ targeting and drug specificity.

Drugs may accumulate selectively in particular tissues as a result of active transport pathways. For example, overexpressed transporters cause some anticancer medications to be actively absorbed into rapidly dividing cells, increasing their therapeutic efficacy in tumors but also raising the possibility of harm in other proliferative tissues such as the gut lining or bone marrow.

➢ **Binding to Tissue Components**

Once a drug has entered a tissue, it may bind to specific macromolecules present in the intracellular or extracellular space. Common binding targets include:

- **Proteins**, such as enzymes or structural proteins, which can serve as either sites of action or storage.
- **Lipids**, especially in adipose-rich tissues, were lipophilic drugs dissolve and store extensively.
- **Nucleic acids**, particularly for drugs targeting DNA or RNA (e.g., some antibiotics and anticancer agents).
- **Mineral structures**, such as bone, where drugs like tetracycline or bisphosphonates can bind to calcium.

The nature of this binding—whether reversible or irreversible, high or low affinity—plays a crucial role in determining a drug's duration of action and potential toxicity.

➢ **Physiological and Pathological Influences**

Age, body composition, tissue pH, blood flow, and other physiological variables all affect tissue binding, which is dynamic. For instance, alterations in tissue composition and binding sites may result in altered medication distribution in an aged or obese person. In addition to

altering the expression of transporter proteins and the integrity of tissue barriers, pathological circumstances such as inflammation, ischemia, or cancer can also change how medications are absorbed and retained in the tissues they affect.

Moreover, drug entrapment is influenced by pH partitioning. Weak acids may concentrate in alkaline tissues, whereas weakly basic medications may build up in acidic tissues (such as inflammatory or diseased areas). Both the therapeutic and toxicological characteristics of medications may be impacted by this phenomenon.

7.3.2 Clinical Implications of Tissue Binding

Drugs' ability to attach to tissues can have important therapeutic ramifications. The duration of action of the medicine is one of the most significant parameters impacted by tissue binding. Even after the plasma concentration has decreased, drugs that bind widely to tissue reservoirs may continue to have an impact. For instance, some antibiotics or antipsychotic drugs can have long-lasting effects even after they are no longer detectable in the bloodstream if they build up in tissues like the liver or fat. In certain therapeutic situations, such as when long-lasting benefits are sought (as in the treatment of chronic illnesses), this extended duration of action may be advantageous. However, if the drug is gradually released from tissue storage over time, it may also raise the risk of drug toxicity.

The possibility of tissue-specific toxicity is an additional clinical effect of tissue binding. Localized harm may result from a medication's accumulation in a specific organ or tissue, particularly if the substance is not effectively eliminated or metabolized there. For instance, it is known that certain anticancer medications can build up in organs such as the liver or bone marrow, which may result in toxicities like hepatotoxicity or myelosuppression (bone marrow suppression). Similar to this, some anesthetics or sedatives might build up in the brain or fat tissues, which could cause neurotoxicity or extended sedation.

7.3.3 Tissue Binding and Drug Disposition

Tissue binding affects a drug's clearance and half-life, among other aspects of its overall disposition. Because they are gradually released back into the bloodstream over time, drugs that bind extensively to tissues may have a long half-life. This may have an impact on when and how often drugs are administered, as well as whether some groups require dose modifications. Because the drug may accumulate more in their tissues, patients with altered tissue composition—such as those with obesity (more fat tissue) or specific cancers—may have

different pharmacokinetics than the general population. To attain the best possible therapeutic results, this may call for modifying medication compositions or dosage schedules.

Furthermore, the volume of distribution (Vd), a pharmacokinetic measure that indicates how widely a drug is dispersed throughout the body, is influenced by tissue binding. Drugs with a high Vd, which indicates that they are broadly dispersed outside of the bloodstream, usually bind to tissues extensively [10]. Comprehending the correlation between tissue binding and Vd is crucial for precisely forecasting a drug's physiological action and refining dosage regimens.

7.3.4 Tissue Binding in Drug Toxicity

Although tissue binding is frequently advantageous for extending the duration of a medication's action and improving therapeutic effects, it can also have unintended consequences when it increases drug toxicity. A medication may become trapped in particular organs when it binds to tissues extensively, accumulating to potentially lethal amounts. For medications with limited therapeutic windows, where there is little difference between dangerous and beneficial dosages, this buildup is especially worrisome.

Organ-specific toxicity is among the most frequent and important clinical effects of tissue accumulation. Drug-induced damage frequently occurs in the liver, which is a key organ for drug processing. Tissue binding-induced hepatotoxicity might show up as fibrosis, inflammation, elevated liver enzymes, or in extreme situations, abrupt liver failure. Because of their affinity for hepatic tissues, medications like methotrexate, isoniazid, and several antiretrovirals are recognized to have the potential to be hepatotoxic. Such tissue formation may present a much higher danger in people with pre-existing hepatic disorders, requiring more frequent monitoring and cautious use.

Likewise, another significant instance of toxicity associated with tissue binding is nephrotoxicity, or drug-induced kidney damage. Because of their high perfusion and role in drug excretion, the kidneys are especially vulnerable to the buildup of nephrotoxic substances. For example, it is known that aminoglycoside antibiotics can attach to renal tubular cells and interfere with cellular activity, resulting in tubular necrosis and impaired renal function. Treatment may become more difficult if these medications' gradual release from kidney tissues prolongs exposure and delays recovery.

When tissue binding affects cardiac tissues, cardiotoxicity is also a serious worry. At high quantities, medications like digoxin, which binds only to heart muscle, can become toxic and cause bradycardia, arrhythmias, and other potentially fatal problems. Once toxicity starts, it

can be challenging to control because of the sluggish clearance from heart tissue, which might maintain these effects long after plasma levels have decreased.

Amiodarone, a highly lipophilic antiarrhythmic agent that builds up in lung tissue, is one medication that can cause pulmonary toxicity. Long-term exposure in the pulmonary tissues can cause pulmonary fibrosis or interstitial pneumonitis, which can seriously limit breathing and may not be reversible.

Another effect of tissue-specific accumulation is neurotoxicity, particularly for medications that attach to glial or neuronal tissues after passing through the blood-brain barrier. Certain drugs, including chlorpromazine or other anesthetics, can build up in the brain and cause extrapyramidal symptoms, depression of the central nervous system (CNS), or cognitive impairment. These effects, especially in older or neurologically challenged patients, can be difficult to reverse and last for a long time.

Because variations in tissue composition, organ perfusion, and metabolic capacity might affect drug binding and accumulation, the risk of tissue-specific toxicity is increased in special groups, such as the elderly, pediatric patients, or those with organ dysfunction. Even conventional dosages may have unanticipated tissue levels and negative effects in these situations.

Clinical practice benefits greatly from therapeutic drug monitoring (TDM) due to the intricacy of tissue binding and its toxicological ramifications. TDM helps with dosage adjustment and toxicity avoidance by enabling clinicians to monitor plasma drug concentrations and deduce tissue distribution patterns. Furthermore, while designing clinical trials and developing new drugs, pharmacokinetic modeling and simulations might assist in predicting tissue accumulation patterns.

7.4 CYTOCHROME P450-BASED DRUG INTERACTIONS

Mostly found in the liver and intestine, cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing enzymes that are essential to the metabolism of numerous medications [11]. These enzymes are in charge of oxidative biotransformation, which transforms lipophilic substances into metabolites that are more hydrophilic and easier to eliminate.

10.5281/zenedo.15960797



Figure 3: Cytochrome P450 in Drug Metabolism

CYP450 enzymes play a key role in drug metabolism, making them a prime location for possible drug-drug interactions (DDIs), which have the ability to drastically change the safety and effectiveness of medications.

7.4.1 Role of CYP450 Enzymes in Drug Metabolism

Drug and xenobiotic metabolism in the body depends on the cytochrome P450 (CYP450) enzyme family. Although the intestinal wall and other tissues also contain considerable numbers of these enzymes, the liver is where they are mostly concentrated. Based on its structure and function, each CYP isoenzyme plays a unique role in the metabolism of particular substrates. Only a small number of the many CYP enzymes that have been discovered—including CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2—are in charge of the majority of drug metabolism in humans[12].

About half of all medications used in clinical practice are metabolized by CYP3A4, the most prevalent and clinically important isoenzyme. With a wide range of substrate specificity, it can handle drugs including calcium channel blockers, benzodiazepines, statins, and immune suppressants like cyclosporine. It also plays a crucial role in the first-pass metabolism of medications taken orally, which directly affects their bioavailability due to its activity in the liver and intestine.

Another important enzyme is CYP2D6, albeit genetic variations cause significant variation in its expression between individuals. Beta-blockers, antidepressants, opioids (such as codeine), and antipsychotics are among the medication types it is in charge of metabolizing. CYP2D6

activity may be low or absent in certain people, referred to as poor metabolizers, which can result in decreased clearance and increased toxicity or impact of the drug. Ultra-rapid metabolizers, on the other hand, could degrade medications too quickly, leading to subtherapeutic levels and therapy failure.

Nonsteroidal anti-inflammatory medications (NSAIDs), oral anticoagulants such as warfarin, and certain antidiabetic medications are metabolized by CYP2C9. Particularly for medications with narrow therapeutic indices, where even little variations in plasma concentration might have major clinical ramifications, polymorphisms in this enzyme can result in markedly changed drug metabolism.

Proton pump inhibitors, antiepileptic medications, and antiplatelet medications such as clopidogrel are all metabolized by CYP2C19. When customizing antiplatelet medication for cardiovascular disease, genetic differences in CYP2C19 are especially significant since they can affect drug responsiveness.

While not as extensively implicated in drug metabolism as CYP3A4, CYP1A2 is crucial for the breakdown of theophylline, caffeine, and several antipsychotics. Lifestyle choices like smoking can increase its activity by accelerating the substrates' clearance.

These CYP enzymes have the ability to either inactivate pharmaceuticals by changing them into more polar, excretable forms or activate prodrugs, which are treatments that need to undergo metabolic conversion in order to become active. For instance, CYP2D6 converts codeine into morphine, which has analgesic properties. On the other hand, CYP3A4 produces an inactive metabolite that is easily eliminated when midazolam is metabolized.

7.4.2 Inhibition of CYP450 Enzymes

CYP450 (cytochrome P450) enzyme inhibition is one of the most important ways that drugs interact with one another[13]. The ability of a particular CYP enzyme to metabolize its typical substrates is diminished when a medicine or chemical inhibits that enzyme. Consequently, medications that rely on that metabolic route build up within the body, resulting in increased plasma concentrations. In addition to raising the possibility of dose-related toxicity, this accumulation can lengthen the duration and intensity of a drug's pharmacological action.

There are two types of CYP inhibition: reversible and irreversible. When an inhibitor attaches to the enzyme momentarily, it reduces its activity without having a lasting effect. This is known as reversible inhibition. Usually, this effect can be avoided by stopping the inhibitor. On the other hand, irreversible inhibition—also referred to as mechanism-based inhibition—occurs

when an inhibitor and enzyme create a stable complex, which frequently results in the destruction of the enzyme or its permanent inactivation. In this instance, the manufacture of new enzyme molecules is necessary for the recovery of enzyme activity, which prolongs the action even after the inhibitor is removed.

Severe CYP3A4 inhibitor ketoconazole is a well-known example of severe reversible inhibition. Ketoconazole can dramatically lower the metabolism of medications such as cyclosporine, simvastatin, or midazolam when taken with them. Serious side effects including rhabdomyolysis (when simvastatin is used) or prolonged sedation (when midazolam is used) may result from this. Because of these interactions, it is necessary to either avoid the combination, change the dosage, or choose different drugs that are not broken down by the enzyme that is inhibited.

Another well-known natural inhibitor of intestinal CYP3A4 is grapefruit juice. Furanocoumarins found in it, such as bergamottin, attach to this enzyme and permanently inhibit it. The gastrointestinal tract's enterocytes are the primary site of inhibition, which increases the medications' absorption and bioavailability. Benzodiazepines, immune suppressants, statins, and calcium channel blockers (such as felodipine) are among the drugs that are frequently impacted. Patients are frequently advised to avoid grapefruit products when taking certain medications because of the potential for unexpected drug buildup and negative effects [14].

A number of variables, such as the inhibitor's potency, the affected enzyme's role in medication clearance, the substrate drug's therapeutic index, and the patient's general health, influence the clinical significance of CYP inhibition. Even slight increases in plasma concentration for medications having a narrow therapeutic index (such digoxin, theophylline, or warfarin) might have detrimental effects. Thus, preventing negative consequences requires recognizing and controlling any CYP-mediated interactions.

7.4.3 Induction of CYP450 Enzymes

A pharmacokinetic phenomenon known as "enzyme induction" occurs when specific drugs increase the expression of cytochrome P450 (CYP450) enzymes, hence enhancing their activity. Drugs that are substrates for the stimulated enzymes experience a faster metabolism as a result, which may lower their plasma concentrations and overall therapeutic efficacy. Enzyme induction typically takes days to weeks to completely manifest, in contrast to inhibition, which frequently has effects right away. The reason for this delay is that induction

entails genetic upregulation, where inducers promote the transcription of genes that code for CYP enzymes.

Significant clinical ramifications may result from CYP enzyme induction, especially when medications with a limited therapeutic index are involved. Drug levels drop below the therapeutic range as metabolism rises, raising the possibility that treatment won't work. Rifampin, a strong inducer of CYP3A4, CYP2C9, and CYP2C19, is a well-known example. Rifampin can significantly lower the plasma concentrations of medications such oral contraceptives, protease inhibitors, anticoagulants, and antiepileptics when taken alongside them. For example, when using oral contraceptives, metabolic induction may cause hormone levels to fall below the recommended range, which could result in unwanted births. Likewise, decreased antiretroviral medication levels in HIV patients may jeopardize viral suppression and raise the possibility of resistance [15].

Aside from rifampin, additional recognized inducers that can increase the metabolic activity of certain CYP isoenzymes include carbamazepine, phenobarbital, phenytoin, St. John's Wort, and smoking. The ability of St. John's Wort, a popular herbal antidepressant, to activate CYP3A4 and P-glycoprotein is especially noteworthy because it lessens the effectiveness of medications like digoxin, cyclosporine, and antidepressants.

Importantly, dietary variables, environmental pollutants, and chronic alcohol consumption can all affect the expression of CYP enzymes, making enzyme induction not just a function of medicinal drugs. Individual genetic variability also comes into play because different nuclear receptors, like the constitutive androstane receptor (CAR) or pregnane X receptor (PXR), which mediate the transcriptional regulation of CYP genes, may cause some people to react more strongly to inducers than others.

The persistence of induction is another important feature. Depending on the enzyme's half-life and the type of inducer, the effects on enzyme activity may last for days or even weeks after the inducer has been removed. This has significant clinical ramifications, particularly when switching between medication treatments. For instance, a patient who stops taking rifampin can continue to have increased drug metabolism for a while, requiring short-term changes to the dosage of other drugs taken at the same time.

Anticipating enzyme induction is crucial in clinical settings to guarantee therapeutic efficacy and avoid less than ideal treatment results. This frequently entails changing drug dosages or choosing substitute drugs that are unaffected by induction. To keep drug levels within the

intended range, therapeutic drug monitoring may also be used, especially for medications that call for exact dosage.

7.4.4 Genetic Variability and Drug Interactions

The activity of cytochrome P450 (CYP450) enzymes, which in turn influences how medicines are digested in various people, is mostly determined by genetic variability. Of these genetic changes, polymorphisms—natural variations in genes—that might change the production or function of CYP450 enzymes are among the most clinically relevant. Drug safety and efficacy may be significantly impacted by this interindividual heterogeneity, especially when paired with drug-drug interactions that further alter enzyme function.

One of the most studied enzymes in this context is CYP2D6, which is responsible for the metabolism of many drugs, including beta-blockers, antidepressants, and opioids like codeine. The CYP2D6 gene exhibits extensive polymorphism, giving rise to a range of metabolic phenotypes:

- **Poor Metabolizers (PMs)**, who have little to no functional enzyme activity;
- **Intermediate Metabolizers (IMs)**, with reduced activity;
- **Extensive Metabolizers (EMs)**, considered the "normal" or wild-type phenotype; and
- **Ultra-Rapid Metabolizers (UMs)**, who have multiple copies of the CYP2D6 gene and hence, very high enzyme activity.

Drug reaction is greatly impacted by this variance. For instance, in order to produce analgesia, CYP2D6 must transform the prodrug codeine into its active form, morphine. This conversion is quite effective in ultra-rapid metabolizers, which can result in dangerously elevated blood levels of morphine, which can cause respiratory depression or even death. However, because they are unable to produce enough morphine, poor metabolizers may get little or no pain relief from codeine. Co-administration of a CYP2D6 inhibitor, like paroxetine or fluoxetine, can reduce even normal enzyme activity, thereby converting an extensive metabolizer into a functional poor metabolizer and changing the course of treatment [16].

Similarly, genetic variants affecting drug metabolism similarly affect CYP2C19 and CYP3A5. For instance, the metabolism of the antiplatelet medication clopidogrel is impacted by CYP2C19 SNPs. Poor cardiovascular outcomes may result from patients with reduced-function alleles' inability to properly activate clopidogrel. The chance of therapeutic failure rises if these individuals are also taking medications that block CYP2C19, such as certain proton pump inhibitors (omeprazole, for example).

Given that pharmacogenetic variability can alter the kind and severity of drug-drug interactions, these genetic variations highlight the intricacy of drug interactions. Depending on their CYP genotypes, two people receiving the same medication combination may have very different results. Personalized medicine, which aims to customize medication therapy to a person's genetic composition, has grown as a result of this. Patients who are at risk of adverse medication reactions or therapeutic failure because of genetic variability in CYP enzymes are increasingly being identified using clinical methods such as pharmacogenetic testing.

7.5 DRUG INTERACTIONS WITH TRANSPORTERS

Because they control the absorption, distribution, and disposal of medications, drug transporters are essential in defining their pharmacokinetics. These transporters facilitate the passage of medications across cellular membranes and are found in a variety of tissues, including the intestinal epithelium, liver, kidney, and blood-brain barrier. Similar to interactions involving metabolizing enzymes like those from the cytochrome P450 family, drug interactions with these transporters can drastically change therapeutic efficacy and safety [17].

7.5.1 Types of Drug Transporters

The ATP-binding cassette (ABC) transporters and the solute carrier (SLC) transporters are the two main groups of drug transporters that are engaged in interactions that are clinically meaningful. The most extensively researched of the ABC transporters is P-glycoprotein (P-gp). It functions as an efflux pump that releases medications from cells, especially at barriers such as the blood-brain barrier and the gut lining. Organic cation transporters (OCTs) and organic anion transporting polypeptides (OATPs) are members of the SLC family. They usually act as influx transporters, making it easier for drugs to enter cells.

7.5.2 Mechanisms of Transporter-Based Drug Interactions

When two or more medications interact with the same transporter, either by blocking its activity or by vying for its binding sites, this is known as a transporter-based drug interaction. The therapeutic effects of the medicine may be impacted by these interactions, which may result in changed drug concentrations in the blood, tissues, or particular organs. A drug's absorption, distribution, metabolism, and excretion (ADME) can be greatly impacted by the inhibition or competition of transporters, which are in charge of regulating the passage of pharmaceuticals across biological membranes [18]. This could result in negative consequences or therapeutic failure.

- **Inhibition of Transporters**

The blockage of a transporter by a co-administered drug is one of the most prevalent mechanisms of transporter-based drug interactions. The passage of a substrate substance across cell membranes can be slowed down or stopped when a medication inhibits the action of a transporter. For instance, the efflux transporter P-glycoprotein (P-gp) is in charge of pumping a variety of medications out of cells, such as intestinal epithelial cells and blood-brain barrier cells. The efflux of other medications that are substrates of this transporter is decreased when a medication inhibits P-gp. The drug's pharmacologic effects may be enhanced, but the danger of toxicity is also increased, as a result of increased drug concentrations in the cells or systemic circulation.

For example, the calcium channel blocker verapamil is a strong P-gp inhibitor. Digoxin is a cardiac glycoside that is a recognized P-gp substrate. When taken with digoxin, verapamil prevents digoxin from being transported out of cells, which raises digoxin plasma levels. Digoxin poisoning, which can cause arrhythmias, nausea, vomiting, and even potentially deadly cardiac events, can be greatly increased by this. Likewise, medications such as the antifungal drug ketoconazole are potent inhibitors of P-gp and a number of CYP450 enzymes, which raises the plasma levels of other medications processed by these systems and increases the risk of side effects.

- **Competition for Transporter Binding Sites**

When two medications vie for binding to the same transporter, this is another typical mechanism of transporter-based drug interactions. The pharmacokinetics of one or both medications may be changed by this kind of interaction, which may result in decreased uptake or greater efflux. For instance, the influx of medications into liver cells is caused by organic anion-transporting polypeptides (OATPs), which are substrates for many pharmaceuticals. The hepatic uptake of one or both medications may be decreased when two medications that are substrates for the same OATP isoform (such OATP1B1) are given together because they may compete for binding to the transporter[19].

The interaction between statins (such as atorvastatin and simvastatin) and gemfibrozil, a fibrate medication used to reduce cholesterol, is a real-world example. Gemfibrozil can reduce the absorption of statins into the liver because it inhibits OATP1B1, which is principally responsible for transporting statins into hepatocytes. This leads to elevated statin plasma levels, which increases the risk of myopathy and rhabdomyolysis, two potentially fatal diseases marked by kidney damage and muscle breakdown.

- **Impact on Drug Absorption**

Drug absorption can also involve transporter-mediated interactions, especially in the intestines. Many medications used orally have their absorption controlled by gut wall influx transporters, including P-gp. A co-administered drug's absorption rate and bioavailability may be impacted when one medication inhibits these transporters. For example, grapefruit juice, which inhibits intestinal CYP3A4 and P-gp, can make medications that are substrates of these transporters more bioavailable. One such medication is the calcium channel blocker felodipine. Higher blood medication concentrations and a higher chance of side effects like edema or hypotension result from this.

Similarly, by enhancing the efflux of other medications from intestinal cells, the antibiotic rifampin, which causes P-gp, can reduce the absorption of other medications. Especially for medications with narrow therapeutic indices like digoxin, this might result in subtherapeutic drug levels, decreasing efficacy and perhaps leading to treatment failure.

- **Role of Transporter Polymorphisms**

Drug interactions may become even more complex due to genetic differences in transporter proteins[20]. Interindividual heterogeneity in transporter expression and function can result from polymorphisms in transporter genes, such as the ABCB1 gene that codes for P-gp. P-gp expression may be elevated in certain people, which could result in higher drug efflux and possibly decreased medication efficacy. Others might have decreased activity or expression, which would raise medication concentrations and raise the possibility of negative side effects.

In these situations, genetic screening can assist in identifying people who could be more susceptible to drug interactions mediated by transporters. For instance, when taking statins, patients with specific genetic variations of OATP1B1 may have changed drug disposition, requiring dosage changes or alternate treatments to reduce the risk of muscle toxicity.

BIBLIOGRAPHY

1. Kutumova, E. O., Akberdin, I. R., Kiselev, I. N., Sharipov, R. N., Egorova, V. S., Syrocheva, A. O., ... & Kolpakov, F. A. (2022). Physiologically based pharmacokinetic modeling of nanoparticle biodistribution: a review of existing models, simulation software, and data analysis tools. *International Journal of Molecular Sciences*, *23*(20), 12560.
2. Laisney, M., Heimbach, T., Mueller-Zsigmondy, M., Blumenstein, L., Costa, R., & Ji, Y. (2022). Physiologically based biopharmaceutics modeling to demonstrate virtual bioequivalence and bioequivalence safe-space for ribociclib which has permeation rate-controlled absorption. *Journal of pharmaceutical sciences*, *111*(1), 274-284.
3. Laws, M., Shaaban, A., & Rahman, K. M. (2019). Antibiotic resistance breakers: Current approaches and future directions. FEMS Microbiology Reviews, 43, 490–516.
4. Lee, J. B., Zhou, S., Chiang, M., Zang, X., Kim, T. H., & Kagan, L. (2020). Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling. *Biopharmaceutics & Drug Disposition*, *41*(4-5), 192-205.
5. Li, S., & Xie, F. (2023). Foetal and neonatal exposure prediction and dosing evaluation for ampicillin using a physiologically-based pharmacokinetic modelling approach. *British Journal of Clinical Pharmacology*, *89*(4), 1402-1412.
6. Li, X., Qiu, M., Wang, S., Zhu, H., Feng, B., & Zheng, L. (2020). A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. *Cancer Chemotherapy and Pharmacology*, *85*, 593-604.
7. Li, X., Yang, Y., Zhang, Y. U., Wu, C., Jiang, Q., Wang, W., ... & Zhang, T. (2019). Justification of biowaiver and dissolution rate specifications for piroxicam immediate release products based on physiologically based pharmacokinetic modeling: An in-depth analysis. *Molecular Pharmaceutics*, *16*(9), 3780-3790.
8. Li, Y., Xiao, P., Wang, Y., & Hao, Y. (2020). Mechanisms and control measures of mature biofilm resistance to antimicrobial agents in the clinical context. ACS Omega, 5, 22684–22690.

9. Li, Y., Zhang, T., Liu, Q., & He, J. (2019). PEG-derivatized dual-functional nanomicelles for improved cancer therapy. Frontiers in Pharmacology, 10.
10. Lim, Y. P., Pang, S. F., Yusoff, M. M., Abdul Mudalip, S. K., & Gimbun, J. (2019). Correlation between the extraction yield of mangiferin to the antioxidant activity, total phenolic and total flavonoid content of Phaleria macrocarpa fruits. Journal of Applied Research on Medicinal and Aromatic Plants, 14, 100224.
11. Litou, C., Turner, D. B., Holmstock, N., Ceulemans, J., Box, K. J., Kostewicz, E., ... & Dressman, J. (2020). Combining biorelevant in vitro and in silico tools to investigate the in vivo performance of the amorphous solid dispersion formulation of etravirine in the fed state. *European Journal of Pharmaceutical Sciences*, *149*, 105297.
12. Liu, J., Li, X., Zhang, H., Chen, G., Chen, H., Hu, Y., ... & Ding, Y. (2019). Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial. Die Pharmazie-An International Journal of Pharmaceutical Sciences, 74(11), 688-693.
13. Loisios-Konstantinidis, I., & Dressman, J. (2020). Physiologically based pharmacokinetic/pharmacodynamic modeling to support waivers of in vivo clinical studies: current status, challenges, and opportunities. *Molecular pharmaceutics*, *18*(1), 1-17.
14. López-Estévez, A. M., Lapuhs, P., Pineiro-Alonso, L., & Alonso, M. J. (2024). Personalized cancer nanomedicine: overcoming biological barriers for intracellular delivery of biopharmaceuticals. *Advanced Materials*, *36*(14), 2309355.
15. Ma, Y., Xue, J., Zhao, Y., Zhang, Y., Huang, Y., Yang, Y., ... & Zhao, H. (2023). Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. *Journal for ImmunoTherapy of Cancer*, *11*(6), e006654.
16. Macheras, P., & Tsekouras, A. A. (2023). *Revising oral pharmacokinetics, bioavailability and bioequivalence based on the finite absorption time concept*. Springer Nature.
17. Mackie, C., Arora, S., Seo, P., Moody, R., Rege, B., Pepin, X., ... & Rullo, G. (2024). Physiologically based biopharmaceutics modeling (PBBM): best practices for drug product quality, regulatory and industry perspectives: 2023 workshop summary report. *Molecular Pharmaceutics*, *21*(5), 2065-2080.

18. Macwan, J. S., Fraczkiewicz, G., Bertolino, M., Krüger, P., & Peters, S. A. (2021). Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: the case of bisoprolol. *CPT: Pharmacometrics & Systems Pharmacology*, *10*(6), 622-632.

19. Madny, M. A., Deshpande, P., Tumuluri, V., Borde, P., & Sangana, R. (2022). Physiologically based biopharmaceutics model of vildagliptin modified release (MR) tablets to predict in vivo performance and establish clinically relevant dissolution specifications. *AAPS PharmSciTech*, *23*(4), 108.

20. Markovic, M., Ben-Shabat, S., & Dahan, A. (2020). Computational simulations to guide enzyme-mediated prodrug activation. International journal of molecular sciences, 21(10), 3621.